Co-Diagnostics, Inc. Announces Third Quarter 2024 Earnings Release Date and Webcast

SALT LAKE CITY, Oct 25, 2024 /PRNewswire/ — Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will report its third quarter 2024 results Thursday, November 7, 2024after market close. The company will also host a conference call and webcast on the same day 4:30 p.m. ET discuss its financial results with analysts and institutional investors. Managing the call includes the following: Dwight EganManaging Director, Brian BrownCFO and Andrew BensonHead of Investor Relations.

The conference call and webcast are available via:

Webcast: ir.codiagnostics.com on the Events and webcasts Page

Conference call: 844-481-2661 (domestic) or 412-317-0652 (international)

If you are unable to attend the live webcast, the call will be recorded and later made available on the company’s website.

About Co-Diagnostics, Inc.

Co-Diagnostics, Inc., a Utah Corporation is a molecular diagnostics company that develops, produces and markets state-of-the-art diagnostic technologies. The Company’s technologies are used for tests aimed at detecting and/or analyzing nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to develop specific tests for its Co-Dx home and point-of-care PCR platform and to pinpoint genetic markers for use in applications other than infectious diseases.

View original content to download multimedia:

SOURCE Co-diagnosis